ADPT

SEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 474,938

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000018 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,885

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 460,216

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 479,276

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000018 · form4.xml · derivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,607

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 464,554

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.14 to $13.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 480,876

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.07 to $12.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000018 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 483,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000016 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,329

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 468,892

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.82 to $14.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 487,952

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000016 · form4.xml · derivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,051

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 473,230

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.98 to $14.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 492,290

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000016 · form4.xml · derivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 184,773

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 477,568

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.45 to $13.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000016 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 496,628

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000014 · form4.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 199,495

Underlying: Common Stock · 14,722 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 481,906

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.51 to $14.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 500,966

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000014 · form4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 214,217

Underlying: Common Stock · 10,783 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000014 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,939 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 486,244

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 505,304

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 494,521

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000014 · form4.xml · derivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,939

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 490,582

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000014 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 509,642

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000012 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,661

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 494,920

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 513,980

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000012 · form4.xml · derivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,383

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 499,258

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 518,318

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000012 · form4.xml · derivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,105

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 503,596

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $13.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000012 · form4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 522,656

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000008 · form4.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,827

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 507,934

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.76 to $13.19, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 526,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000008 · form4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,549

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 512,272

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.12 to $13.76, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 517,672

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.11 to $13.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 531,332

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780649-26-000007 · form4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,301,113

F2 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance share units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780649-26-000007 · form4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,630,713

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780662-26-000006 · form4.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 259,840

F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001780660-26-000011 · form4.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 291,374

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000008 · form4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,271

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000008 · form4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 516,610

F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.83 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.